Based at the Cambridge Science Park since its foundation in 2007, Hypoxium specializes in cell biology within the oncology therapeutic area. The new services provided by HDS include a suite of X-MAN Pathway assays that combine Horizon’s genetically defined isogenic X-MAN human disease models with Hypoxium expertise in mimicking the tumor microenvironment in an in vitro setting.

To support internal R&D that will further expand the suite of services provided by HDS, Horizon is investing $500,000 in a two-year research program. The program will add assays to the X-MAN Pathways panel and format these into high-throughput and relevant in vivo assays to be operated by Horizon’s U.S. partner, TGEN Drug Development.

One of the challenges that cancer researchers face in designing therapeutics is that of predicting how drug molecules will behave in the complex microenvironment that surrounds a tumor. HDS will thus aid in the identification of how specific cancer genes and assay conditions such as hypoxia, growth-factors, and nutrient supplies affect sensitivity to therapeutic compounds.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.